🔗 Share this article

A shadow economy for unlicensed slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.

Experimental Drug Gaining Popularity Via Social Media

The experimental drug, which remains in research studies, is being promoted by social media influencers for its alleged fat-burning effects. Followers are encouraged to contact these profiles directly for supplier links, while also obtaining discount codes.

Thriving Trade on Social Networks

Separately, a robust trade exists on messaging services, where groups with numerous of participants share comparison photos, injection guides and assertions of rapid UK delivery. Sellers market the substance there before directing customers to other platforms for transactions.

Understanding Retatrutide

Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist individuals reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed online as the successor to Ozempic.

Medical Professionals Express Worries

However, physicians and chemists have warned that the sale of what is still an unlicensed drug in the UK is a cause for concern and could lead to individuals injecting substances of uncertain source.

Several professionals said the popularity for retatrutide could be linked to the increasing price of approved weight loss products such as Mounjaro.

Legal Status and Implementation

Selling retatrutide on TikTok or Telegram is illegal in the UK, as it is an unlicensed medication that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators attempt to sidestep the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still violate pharmaceutical, advertising, and consumer regulations, potentially leading to penalties, prosecution or imprisonment.

Platform Response and Material Removal

According to the social media company, the service has removed problematic material and prohibited related keywords and query recommendations. The company said it was committed to keeping the service safe and investing in strengthening enforcement strategies.

Online Trading Activities

Investigations also found groups with up to 9,000 participants selling retatrutide using the platform's built-in search feature, which operates like a online catalog. Typing “retatrutide” immediately brings up channels with thousands of users, populated with photos of weight loss, positive testimonials and detailed instructions for mixing or administering at home.

Within minutes of joining one group, a seller posted WhatsApp details, where most transactions occur. The seller provided an guidebook and guaranteed shipping within 48 hours. When questioned whether the product was authentic, one seller responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. Not one inquired about weight, medical conditions or past usage.

Product Information and Pricing

Inside these groups, posts show dark colored parcels with postal service stickers, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at residence with purified liquid, or pre-filled pens typically priced at £160 for 20 milligrams. When asked how long a pen should last, sellers give contradictory responses ranging from a several days to “depends on your body”.

Service Oversight and Safety Actions

A representative for Telegram said it actively moderated dangerous material on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“People are administering substances they can’t verify. Although the research behind retatrutide is sound, these digital versions may not include what they claim,” stated Jason Murphy, the head of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the surge in interest to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, patients are using social media. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were made in was clean,” she said.

Her staff has previously seen patients injured by personal administration from unconfirmed sources. “We recognize the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they explained, adding that any product “misleadingly claiming itself as a company investigational product not yet authorized … may subject users to potentially significant medical dangers”.